businesspress24.com - hVIVO to Present at the 2016 BIO Investor Forum
 

hVIVO to Present at the 2016 BIO Investor Forum

ID: 1463517

(firmenpresse) - LONDON, UNITED KINGDOM -- (Marketwired) -- 10/13/16 -- hVIVO plc (AIM: HVO), a specialty biopharma company with clinical testing capabilities, today announced that it will be presenting at the 2016 BIO Investor Forum in San Francisco on Tuesday, October 18, 2016 at 11:30 a.m. PT (2:30 p.m. ET, 7:30 p.m. GMT).

A live audio webcast of the presentation will be available in the section of the hVIVO website at . A webcast replay will be available on the website for 90 days following the live presentation.

About BIO

BIO is the world''s largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the , the world''s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world.

About hVIVO

hVIVO plc ("hVIVO"), a specialty biopharma company with clinical testing capabilities, is pioneering a human-based analytical platform to accelerate drug discovery and development in respiratory and infectious diseases. Leveraging human disease models in flu, RSV, and asthma exacerbation, the hVIVO platform captures disease in motion, illuminating the entire disease life cycle from healthy to sick and back to health. Based in the UK, market leader hVIVO has conducted more than 45 clinical studies, inoculated over 2,250 volunteers and has three first-in-class therapies currently in development with a growing pre-clinical pipeline. For more information, please visit , , and .



For further information, please contact:

hVIVO plc
+44 207 756 1300

Kym Denny (Chief Executive Officer)
Graham Yeatman (Chief Financial & Business Officer)





Media Enquiries
+44 203 021 3933 / +44 7854 979 420

Colin Paterson (Director of Marketing, Communication and Public Relations)

Numis Securities Limited
+44 207 260 1000
Michael Meade / Freddie Barnfield (Nominated Adviser)
James Black / Michael Burke (Corporate Broking)

Weitere Infos zu dieser Pressemeldung:

Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:



Leseranfragen:



PresseKontakt / Agentur:



drucken  als PDF  an Freund senden  Immunovaccine Announces Positive Phase 1 Topline Data for DepoVax(TM)-based Respiratory Syncytial Virus Vaccine Candidate
Boston Therapeutics Announces Innovation Grant
Bereitgestellt von Benutzer: Marketwired
Datum: 13.10.2016 - 06:30 Uhr
Sprache: Deutsch
News-ID 1463517
Anzahl Zeichen: 3011

contact information:
Contact person:
Town:

LONDON, UNITED KINGDOM


Phone:

Kategorie:

Biotech


Typ of Press Release:
type of sending:
Date of sending:
Anmerkungen:


Diese Pressemitteilung wurde bisher 169 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"hVIVO to Present at the 2016 BIO Investor Forum
"
steht unter der journalistisch-redaktionellen Verantwortung von

hVIVO plc (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).


Alle Meldungen von hVIVO plc



 

Who is online

All members: 10 563
Register today: 2
Register yesterday: 2
Members online: 0
Guests online: 71


Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.